Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 10/20 | 0.49 |
| ▸ | DRD1 | P21728 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438739 | 1.00 | HTT (0.51) | HTTNPC1ALDH1A1RAB9ADRD3 | |
| SCHEMBL29322833 | 0.90 | DRD3 (0.51) | ALDH1A1DRD3DRD1DRD2DRD4 | |
| SCHEMBL21649544 | 0.88 | DRD3 (0.51) | HTTDRD3DRD1DRD2DRD4 | |
| SCHEMBL31134854 | 0.83 | GRM5 (0.64) | NPC1ALDH1A1RAB9ADRD3DRD1 | |
| SCHEMBL5811132 | 0.83 | GRM5 (0.64) | NPC1ALDH1A1RAB9ADRD3DRD1 | |
| SCHEMBL4116833 | 0.83 | NPC1 (0.43) | HTTNPC1ALDH1A1RAB9ADRD3 | |
| SCHEMBL4116828 | 0.83 | NPC1 (0.43) | HTTNPC1ALDH1A1RAB9ADRD3 | |
| SCHEMBL4552575 | 0.82 | DRD3 (0.60) | DRD3DRD1DRD2DRD4GRM5 | |
| SCHEMBL31498948 | 0.82 | NPC1 (0.50) | NPC1ALDH1A1RAB9ADRD3DRD1 | |
| SCHEMBL179103 | 0.81 | KDM4E (0.58) | HTTNPC1RAB9ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113429344-B | Preparation method of 2-ethyl-3, 4-dihydro-1 (2H) -isoquinolinone | 五邑大学 | 2022-03-25 | — | — | CN | claimed |
| CN-113429344-A | Preparation method of 2-ethyl-3, 4-dihydro-1 (2H) -isoquinolinone | 五邑大学 | 2021-09-24 | — | — | CN | claimed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20220153709-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-113429344-B | Preparation method of 2-ethyl-3, 4-dihydro-1 (2H) -isoquinolinone | 五邑大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-113429344-B | Preparation method of 2-ethyl-3, 4-dihydro-1 (2H) -isoquinolinone | 五邑大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-113429344-B | Preparation method of 2-ethyl-3, 4-dihydro-1 (2H) -isoquinolinone | 五邑大学 | 2022-03-25 | — | — | CN | disclosed |
| US-11162101-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-113429344-A | Preparation method of 2-ethyl-3, 4-dihydro-1 (2H) -isoquinolinone | 五邑大学 | 2021-09-24 | — | — | CN | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-3961062-A | Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | HTT 4671/4885NPC1 3728/4885ALDH1A1 3832/4885 |
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | HTT 640/4885NPC1 2258/4885ALDH1A1 4181/4885 |
| US-20220153709-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | HTT 1047/4885NPC1 877/4885ALDH1A1 179/4885 |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | HTT 3224/4885NPC1 2338/4885ALDH1A1 1980/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | HTT 4671/4885NPC1 3728/4885ALDH1A1 3832/4885 |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | HDAC1, HDAC7, HDAC5 | HTT 1047/4885NPC1 877/4885ALDH1A1 179/4885 |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F5 | HTT 4712/4885NPC1 2438/4885ALDH1A1 4067/4885 |
| US-11162101-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | HTT 640/4885NPC1 2258/4885ALDH1A1 4181/4885 |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | HTT 640/4885NPC1 2258/4885ALDH1A1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.